Table II.
Effect of Nebivolol on Blood Pressure and Heart Rate in Patients With Mild to Moderate Hypertension
| Variable | Nebivolol Dose | ||||||
|---|---|---|---|---|---|---|---|
| Placebo | 1.25 mg | 2.5 mg | 5 mg | 10 mg | 20 mg | 40 mg | |
| Trough SiDBP, mm Hg | |||||||
| No. | 81 | 83 | 82 | 165 | 166 | 166 | 166 |
| Baseline mean | 100.3 | 98.9 | 99.8 | 99.6 | 99.5 | 99.4 | 99.3 |
| Mean change (SD) | −3.2 (7.7) | −8.0 (7.7) | −8.7 (7.7) | −8.6 (8.0) | −9.4 (8.1) | −9.9 (8.7) | −11.3 (8.3) |
| LS mean change from baseline (SE)a | −2.9 (1.1) | −8.0 (1.1) | −8.5 (1.1) | −8.4 (1.0) | −9.2 (0.9) | −9.8 (0.9) | −11.2 (0.9) |
| Step‐down trend test P value | <.001 | <.001 | <.001 | <.001 | <.001 | ||
| Trough SiSBP, mm Hg | |||||||
| No. | 81 | 83 | 82 | 165 | 166 | 166 | 166 |
| Baseline mean | 154.9 | 152.2 | 150.1 | 152.6 | 155.8 | 151.9 | 153.1 |
| Mean change (SD) | −4.7 (12.2) | −7.8 (12.0) | −9.0 (14.7) | −9.9 (11.6) | −10.7 (13.2) | −11.5 (14.8) | −13.6 (13.0) |
| LS mean change from baseline (SE)a | +2.2 (1.9) | −4.4 (1.9) | −6.3 (1.9) | −5.9 (1.6) | −7.0 (1.6) | −6.5 (1.6) | −9.5 (1.5) |
| Step‐down trend test P value | .002 | <.001 | <.001 | <.001 | <.001 | ||
| Trough sitting heart rate, bpm | |||||||
| No. | 67 | 69 | 68 | 148 | 136 | 145 | 149 |
| Baseline mean | 73.9 | 72.3 | 73.5 | 72.7 | 71.5 | 73.3 | 71.7 |
| Mean change (SD) | 0.2 (8.7) | −2.7 (8.9) | −4.3 (8.1) | −6.5 (9.0) | −6.5 (8.0) | −9.7 (8.5) | −9.8 (7.8) |
| LS mean change from baseline (SE)a | +2.4 (1.1) | −1.4 (1.1) | −2.4 (1.1) | −4.9 (0.9) | −5.5 (0.9) | −7.9 (0.9) | −8.9 (0.9) |
| Step‐down trend test P value | .002 | <.001 | <.001 | <.001 | <.001 | <.001 | <.001 |
| Abbreviations: bpm, beats per minute; LS, least‐squares; SiDBP, sitting diastolic blood pressure; SiSBP, sitting systolic blood pressure. aFrom an analysis of covariance with factor, treatment, and covariates baseline blood pressure, nebivolol metabolism rate, diabetes status, sex, race, and age group. | |||||||